Benzethonium chloride activates ER stress and reduces proliferation in HNSCC

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world, accounting for 650,000 new cancer diagnoses each year with 350,000 deaths [1]. Despite the high mortality rate and increased public interest in the United States, NIH support for head and neck cancer research has been decreasing and progress in treatments has accordingly lagged egregiously behind more generously funded malignancies [2 –4]. Management of HNSCC over the past 20 years has moved towards an organ preservation approach with most patients being offered a combination of chemotherapy and radiation treatment.

Source: Oral Oncology - November 29, 2017 Category: Cancer & Oncology Authors: Hani M. Rayess, Yue Xi, Danielle M. Garshott, Amy L. Brownell, George H. Yoo, Michael U. Callaghan, Andrew M. Fribley Source Type: research